MA23079A1 - Procede pour le traitement de l'osteoporose utilisant des biphosphonates et l'hormone parathyroide - Google Patents

Procede pour le traitement de l'osteoporose utilisant des biphosphonates et l'hormone parathyroide

Info

Publication number
MA23079A1
MA23079A1 MA23039A MA23039A MA23079A1 MA 23079 A1 MA23079 A1 MA 23079A1 MA 23039 A MA23039 A MA 23039A MA 23039 A MA23039 A MA 23039A MA 23079 A1 MA23079 A1 MA 23079A1
Authority
MA
Morocco
Prior art keywords
biphosphonates
osteoporosis
treatment
parathyroid hormone
parathyroid
Prior art date
Application number
MA23039A
Other languages
English (en)
French (fr)
Inventor
Dunbar Geddes Ann
Waite Boyce Rogely
Original Assignee
Procter & Gamble Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble Pharma filed Critical Procter & Gamble Pharma
Publication of MA23079A1 publication Critical patent/MA23079A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA23039A 1991-12-17 1992-12-16 Procede pour le traitement de l'osteoporose utilisant des biphosphonates et l'hormone parathyroide MA23079A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80962091A 1991-12-17 1991-12-17

Publications (1)

Publication Number Publication Date
MA23079A1 true MA23079A1 (fr) 1993-07-01

Family

ID=25201804

Family Applications (1)

Application Number Title Priority Date Filing Date
MA23039A MA23079A1 (fr) 1991-12-17 1992-12-16 Procede pour le traitement de l'osteoporose utilisant des biphosphonates et l'hormone parathyroide

Country Status (18)

Country Link
US (1) US5616560A (enExample)
EP (1) EP0618805A1 (enExample)
JP (1) JPH07502507A (enExample)
AU (2) AU3322593A (enExample)
BR (1) BR9206941A (enExample)
CA (1) CA2124792C (enExample)
CZ (1) CZ282889B6 (enExample)
FI (1) FI942884A0 (enExample)
HU (1) HUT68010A (enExample)
IL (1) IL104108A (enExample)
MA (1) MA23079A1 (enExample)
MX (1) MX9207349A (enExample)
NO (1) NO942241D0 (enExample)
NZ (1) NZ246456A (enExample)
RU (2) RU2112515C1 (enExample)
SK (1) SK74594A3 (enExample)
WO (1) WO1993011786A1 (enExample)
ZA (1) ZA929758B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT68010A (en) * 1991-12-17 1995-05-29 Procter & Gamble Pharma The use of bisphonates and parathyroid hormone for the treatment of osteoporosis
EP0663919A1 (en) * 1992-10-09 1995-07-26 PHARMACIA & UPJOHN COMPANY Pyrimidine bisphosphonate esters as anti-inflamatories
FR2703590B1 (fr) 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
US6013792A (en) * 1993-08-05 2000-01-11 Syntex (U.S.A.), Inc. Matrix metalloprotease inhibitors
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
CA2199252A1 (en) * 1994-09-09 1996-03-14 Ann Dunbar Geddes Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone
AU686019B2 (en) * 1994-09-09 1998-01-29 Procter & Gamble Company, The Phosphonates and parathyroid hormone for osteoporosis
EP0800405A4 (en) * 1994-12-19 1998-11-11 Beth Israel Hospital CONTINUOUS ADMINISTRATION OF LOW DOSES OF HORMONE PARATHYRO DIENNE OR ITS AGONIST
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
AU701258B2 (en) * 1994-12-28 1999-01-21 Gador S.A. Bone mass anabolic composition comprising olpadronate
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
EP0891779A1 (de) * 1997-06-19 1999-01-20 Roche Diagnostics GmbH Pharmazeutische Kombinationspräparate enthaltend Parathyroidhormon und Calcium- und/oder Phosphatverbindungen
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
EP0922467A3 (en) * 1997-12-12 2000-05-24 Takeda Chemical Industries, Ltd. Iontophoretic drug delivery
RU2155588C2 (ru) * 1998-10-16 2000-09-10 Общество с ограниченной ответственностью "Институт фармацевтических реактивов РЕФАРМ" Способ увеличения массы костной ткани при переломах
JP4486256B2 (ja) * 1998-10-22 2010-06-23 ザ・ジェネラル・ホスピタル・コーポレイション 副甲状腺ホルモン（ＰＴＨ）および副甲状腺ホルモン関連ペプチド（ＰＴＨｒＰ）の生物活性ペプチドおよびペプチド誘導体
WO2000032771A1 (en) 1998-11-30 2000-06-08 The General Hospital Corporation Pth1r and pth3r receptors, methods and uses thereof
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
AU7734800A (en) * 1999-09-29 2001-04-30 General Hospital Corporation, The Polypeptide derivatives of parathyroid hormone (pth)
DK1296689T3 (da) 2000-06-20 2005-11-28 Novartis Ag Fremgangsmåde til indgivelse af bisphosphonater
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
KR100491737B1 (ko) * 2001-07-20 2005-05-27 주식회사 한국아이템개발 공기 정화 기능의 모기 퇴치기
US7572765B2 (en) 2001-07-23 2009-08-11 The General Hospital Corporation Conformationally constrained parathyroid hormone (PTH) analogs
DE60233803D1 (de) * 2001-08-17 2009-11-05 Novartis Ag 5-cnac zur oralen verabreichung von parathormonfragmenten
WO2003086415A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
BR0308901A (pt) 2002-05-10 2005-01-04 Hoffmann La Roche ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
RU2219933C1 (ru) * 2002-07-22 2003-12-27 Волова Лариса Теодоровна Способ стимуляции остеогенеза
US20040097468A1 (en) * 2002-11-20 2004-05-20 Wimalawansa Sunil J. Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
AU2003220380A1 (en) * 2003-03-19 2004-11-19 Bristol-Myers Squibb Company CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH Alpha-HELIX STABILIZERS
ATE410186T1 (de) * 2003-06-26 2008-10-15 Control Delivery Sys Inc In-situ gelierendes arzneimittelabgabesystem
EP1653985A4 (en) 2003-07-17 2009-08-05 Gen Hospital Corp FORCED PARATHORMON (PTH) ANALOGUE
JP2007501241A (ja) * 2003-08-06 2007-01-25 ローディア インコーポレイティド 骨成長を促進する方法
WO2005018640A1 (en) * 2003-08-20 2005-03-03 The Procter & Gamble Company Kit for treatment of upper gastrointestinal tract conditions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
RU2273493C1 (ru) * 2004-10-15 2006-04-10 Валерий Николаевич Зеленков Композиция для профилактики и лечения болезней, вызываемых дефицитом кальция (варианты)
WO2007059470A2 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2008019062A2 (en) * 2006-08-04 2008-02-14 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
MX2009012650A (es) * 2007-05-24 2010-02-18 Ablynx Nv Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
BRPI0814962B8 (pt) * 2007-08-01 2021-05-25 Chugai Pharmaceutical Co Ltd métodos in vitro para determinar se um composto candidato é um agonista de longa duração ou de curta duração de um receptor acoplado à proteína g, polipeptídeo, seu uso e composição farmacêutica
WO2011071480A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
CN103002906B (zh) 2010-05-13 2017-12-29 总医院有限公司 甲状旁腺激素类似物及其应用
WO2016163886A2 (en) 2015-04-10 2016-10-13 Clues2Cure International B.V. Administration of taurine or an analog thereof for the treatment of nerve cell damage
CN111447943A (zh) * 2018-10-29 2020-07-24 旭化成制药株式会社 以按每周2次的频率给予特立帕肽或其盐为特征的骨质疏松症的预防或治疗方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) * 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
DE3243358A1 (de) * 1982-11-24 1984-05-24 Rolf Dieter Prof.Dr. 3004 Isernhagen Hesch Synthetisches humanes (1-38) parathormon-fragment, verfahren zu seiner herstellung und die verwendung zur behandlung der osteoporose
US4822609A (en) * 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
US4812311A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
HUT68010A (en) * 1991-12-17 1995-05-29 Procter & Gamble Pharma The use of bisphonates and parathyroid hormone for the treatment of osteoporosis

Also Published As

Publication number Publication date
AU3022692A (en) 1993-06-24
CZ147794A3 (en) 1994-12-15
ZA929758B (en) 1993-09-10
FI942884A7 (fi) 1994-06-16
MX9207349A (es) 1993-12-01
NO942241D0 (no) 1994-06-15
SK74594A3 (en) 1995-01-12
EP0618805A1 (en) 1994-10-12
HUT68010A (en) 1995-05-29
RU2104699C1 (ru) 1998-02-20
CA2124792A1 (en) 1993-06-24
RU2112515C1 (ru) 1998-06-10
CA2124792C (en) 2000-07-04
HU9401798D0 (en) 1994-09-28
IL104108A0 (en) 1993-05-13
FI942884L (fi) 1994-06-16
CZ282889B6 (cs) 1997-11-12
NO942241L (enExample) 1994-08-09
AU663348B2 (en) 1995-10-05
NZ246456A (en) 1997-03-24
RU94031209A (ru) 1996-07-27
JPH07502507A (ja) 1995-03-16
BR9206941A (pt) 1995-05-02
WO1993011786A1 (en) 1993-06-24
FI942884A0 (fi) 1994-06-16
AU3322593A (en) 1993-07-19
US5616560A (en) 1997-04-01
IL104108A (en) 1999-09-22

Similar Documents

Publication Publication Date Title
DZ1716A1 (fr) Méthode et mécanisme pour l'enlevement et le traitement des déchets.
FR2682100B1 (fr) Procede et dispositif pour l'epuration biologique des eaux residuaires.
ZA929758B (en) Methods for the treatment of osteoporosis using biphosphonates and parathyroid hormone
EP0661966A4 (en) COMPOSITION AND METHOD FOR ULCUS PREVENTION AND TREATMENT.
EP0751709A4 (en) METHODS FOR USE OF BCL-2 IN THERAPEUTIC TREATMENT AND PREVENTION OF DISEASES
FR2667057B1 (fr) Reacteur perfectionne pour le traitement biologique des eaux residuaires.
FR2659784B1 (fr) Procede de traitement de dechets fortementradioactifs.
FR2654936B1 (fr) Procede pour le traitement et l'elimination de dechets medicaux et dispositif pour la mise en óoeuvre du procede.
FR2652759B1 (fr) Catalyseurs pour le traitement des effluents gazeux et procede de traitement de ces effluents.
FR2649391B1 (fr) Procede de traitement de l'acide phosphorique pour en eliminer certains metaux lourds
EP0743927A4 (en) Improved wastewater treatment process
FR2644773B2 (fr) Procede et dispositif pour l'epuration d'eaux polluees
FR2563208B1 (fr) Procede de traitement des eaux par l'ozone
MA22278A1 (fr) Procede pour le traitement de troubles respiratoires
FR2558818B1 (fr) Procede et appareil pour le traitement de l'eau a l'aide d'ozone, prepare en partant de gaz riche en oxygene
FR2674844B1 (fr) Procede et installation de traitement d'epuration de lisiers d'animaux.
FR2619559B1 (fr) Procede pour la regulation des installations d'epuration des eaux residuaires
FR2666080B3 (fr) Composition minerale pour le traitement d'epuration des eaux.
FR2741872B1 (fr) Procede et reacteur biologique pour le traitement de l'eau
FR2621307B3 (fr) Procede d'evacuation et de traitement de boues de decantation provenant de l'epuration d'eaux usees
FR2630727B1 (fr) Procede et dispositif pour le traitement des eaux usees renfermant des nitrites
FR2569423B3 (fr) Procede pour le traitement des cuirs et appareil pour l'execution de ce procede
FR2680123B1 (fr) Procede de traitement de residus fortement polluants pour l'environnement.
FR2679546B1 (fr) Procede de traitement des eaux.
FR2511359B1 (fr) Procede de traitement d'eaux usees par l'ozone